## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($311.87)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Up 37% Since August, Is It Safe to Buy UnitedHealth Group Stock Again?**
- Source: Finviz | 20251204T071046 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) has seen its stock rally 37% since August, despite facing challenges such as rising costs and a DOJ investigation. This rebound was significantly influenced by Berkshire Hathaway's investment, highlighting the stock's perceived value. While UnitedHealth is actively trying to improve its financials and has raised its guidance, it still faces an uncertain path, making patience crucial for investors.

**2. UnitedHealth Group Stock (UNH) Rallies on Analyst Upgrades, Latin America Exit and New ETF: December 3, 2025 Outlook**
- Source: ts2.tech | 20251203T183741 | Bullish | Relevance: 100%
- UnitedHealth Group (UNH) stock rallied on December 3, 2025, driven by analyst upgrades, the company's strategic exit from Latin America, and the launch of a new single-stock ETF. Despite a turbulent year marked by a cyberattack and fraud probe, the stock saw a significant bounce due to a $1.6 billion investment from Warren Buffett and renewed bullish sentiment from Wall Street. The article deep dives into the catalysts, Q3 2025 earnings, strategic recalibrations for Medicare Advantage, and ongoing legal and regulatory challenges facing UNH.

**3. Why UnitedHealth (UNH) Stock Is Up Today**
- Source: Finviz | 20251203T152500 | Bullish | Relevance: 100%
- UnitedHealth (UNH) shares rose 4.5% due to positive analyst actions and strategic company updates, including lifted price targets by Wolfe Research, Bernstein, and RBC Capital. The optimism stems from the belief that UnitedHealth can improve profit margins in its insurance division. This move follows a previous gain tied to hopes for an interest rate cut, though the stock is still significantly down year-to-date.

**4. Groupe la Francaise Reduces Stock Holdings in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251205T120829 | Neutral | Relevance: 100%
- Groupe la Francaise significantly reduced its stake in UnitedHealth Group (UNH) by 97.9% in Q2, selling 27,602 shares and retaining only 596 shares. Despite this, other institutions increased their holdings, with hedge funds now owning approximately 87.86% of UNH stock. Wall Street analysts have a mixed "Hold" consensus, but several have raised price targets, while UnitedHealth Group reported an EPS beat and 12.2% revenue growth, along with a quarterly dividend of $2.21.

**5. Dodge & Cox Has $2.73 Billion Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251205T100926 | Somewhat-Bullish | Relevance: 100%
- Dodge & Cox significantly increased its stake in UnitedHealth Group (NYSE:UNH) by 117.7% in Q2, bringing their total holdings to 8,750,560 shares valued at approximately $2.73 billion. This position represents 1.5% of Dodge & Cox's portfolio, making it their 26th largest holding. UnitedHealth Group has demonstrated strong financial performance, beating quarterly EPS estimates and posting robust revenue growth, and it maintains a consensus "Hold" rating among analysts with an average price target of $385.54.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 8.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 18.6x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $300.6B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 18.6 |
| Current P/E | 20.3 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (2.36), confirming momentum. RSI neutral at 50. OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.45% (CS: 49) | Neutral |
| RSI_14 | 50.1 | Neutral |
| MACD Histogram | 2.36 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 0.967x | Below |
| vs SMA200 | 0.914x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $330.91
- **Stop Loss:** $311.87 (5.8% risk)
- **Target:** $368.99 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $8,603.66
- **Portfolio %:** 8.60%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*